skip to Main Content


The Opportunity

Diabetes are Mediial DeviceBlackhawk Technologies, LLC is exclusively representing HyperMed Imaging Inc. (the“Company”) to monetize its’ assets related to a Medical Device for Tissue Oximetry for Diabetes Care. The offering includes an FDA cleared product used by clinicians and backed by 24 patent families comprising of 62 total assets.

The Company’s pioneering technology has been in service since 2006 and has been validated in third-party published papers that assessed oxyhemoglobin, deoxyhemoglobin, and oxyhemoglobin saturation in superficial tissue for diabetic patients. The Company’s FDA 510(k) cleared product, Hyper View™, quickly determines levels of oxyhemoglobin, deoxyhemoglobin and oxygen saturation in superficial tissue in a small and portable configuration.

The Company seeks a strategic acquirer/licensee with both resources and channels to fully commercialize Company’s IP assets.

The Unmet Medical Need

Most medical exams need quick and accurate determination of superficial tissue oxygenation. For example, complications in diabetes and/or peripheral arterial disease increases risk of lower limb ischemia, chronic wounds, amputation or even death.

• Over 420 million people worldwide (1 in 11 people) have diabetes and the number is increasing rapidly.
• More than 29 million Americans have diabetes. Another 86 million have prediabetes, which is 1 in 3 US adults.
• 8.5 million Americans have peripheral arterial disease and among them nearly 2 million people in the USA are living with limb loss.
• The main causes are vascular disease (54%), including diabetes and peripheral arterial disease.
• Approximately 185,000 amputations occur in the United States each year, costing over $8 billion.
• People with diabetes are at greater risk for severe peripheral arterial disease and are five times more likely to require an amputation.
• It is estimated that a low

Hyperspectral Imaging Benefits

• Non-contact color-coded images depicting concentrations of oxyhemoglobin & deoxyhemoglobin, and oxygen saturation without injectable contrast agents.
• Readings are predictive of wound healing and can be used in screening for peripheral vascular disease.
• Software tools allow clinicians to analyze specified areas within the image to localize ischemic tissue.
• Offers improved patient care with speed, ease of use, and clinical efficiency without injectable contrast or physical contact of the device with the patient.
• Safe, using visible light and spectrometer imaging to quantify light absorption in hemoglobin molecules for rapid analysis without leaving the exam room.

For more details about technology: Click Here


origion corporate Has developed a proprietary device (“IonojetTM”) that generates nitric oxide (“NO”) from atmospheric air in the form of a high-energy plasma/NO stream and delivers it to targeted locations of the body.

The plasma/NO stream has been shown in investigations to date:

(i)to be non-toxic

(ii) to generate NO activity up to 3 cm below the skin

(iii) to stimulate sustained biological activity in tissue for up to an hour after delivery of the therapy, and

(iv) to penetrate and disrupt biofilm

Has identified over 40 target indications in seven clinical areas based on NO’s recognized ability to:

  • Increase blood flow
  • Destroy pathogens (bacterial, viral and fungal)
  • Regenerate tissue
  • Control pain and inflammation

Has completed a dose-ranging feasibility clinical trial in the U.S. for initial target indication (Diabetic Foot Ulcers, “DFU”) to identify optimal dose & demonstrate preliminary safety/efficacy data for the device.

  • Has completed PoC studies in certain target indications
  • Intends to initiate PoC studies in a number of additional indications

For more details about technology: Click Here

Nutrition Innovation In Singapore

nucaneWhite refined sugar is almost pure sucrose. This sucrose is consistently shown in research to be quickly absorbed into the blood stream causing rises in blood sugar levels. This in turn has contributed to the global obesity and diabetes crisis.

The Nucane™ specification of raw sugar is scientifically tested to ensure that this absorption is reduced.What the unique Nucane™ process achieves is to retain at a high level the natural organics, antioxidants and polyphenols that exist in raw sugar cane, delivering a carbohydrate that is less processed, less refined, and which has been demonstrated scientifically to reduce the metabolism of sugar into the blood stream when consumed. This means that it is a low glycemic sugar when tested to the internationally agreed ISO 26442:2010 method.Just as importantly, our technology system ensures that Nucane™ is precise and consistent at industrial scale in primary sugar mills around the world. By eliminating the refining process and applying the Nucane technology at sugar mills, Nucane™ is a less processed, less refined, high in polyphenols specification of raw sugar which has been tested to be low glycemic to international standards.

For more details about technology: Click here

Pop Test & Palisades Therapeutics Companies

Wellness ScreeningWELLNESS Screening/Monitoring


Diagnosed and undiagnosed diabetes in the United States, all ages, 2012, Total: 29.1 million people or 9.3% of the population have diabetes. Diagnosed: 21.0 million people. Undiagnosed: 8.1 million people. (27.8% of people with diabetes are undiagnosed)


Prevalence of NAFLD and NASH is higher than estimated previously. Hispanics and patients with diabetes are at greatest risk for both NAFLD and NASH. Up to 80% of obese people have the disease. Non-alcoholic steatohepatitis (NASH) is the most extreme form of NAFLD, and is regarded as a major cause of cirrhosis of the liver of unknown cause. About 12 to 25% of people in the United States has NAFLD. While NASH affects between 2 to 5% of people in the United States.


Percent of adults age 20 years and over with high serum total cholesterol (greater than or equal to 240 mg/dL): 13.4% (2009-2012)


Gout prevalence swells in U.S. over last two decades; Increase in obesity and hypertension are likely contributors. Prevalence of gout in the United States has risen over the last twenty years and now affects 8.3 million Americans.

For more details about technology: Click here

Compound for Pancreatic Cancer

CancerThe novel compound focuses on inhibiting tumor growth and synergy with chemo in select cancers by targeting Pancreatic Cancer Stem Cells (PanCSCs), which could be an ideal therapy to overcome chemoresistance. The compound tends to be a cutting edge science focused on large critical disease markets. This anti cancer compound invented by Dr. Gurdial Singh has the potential to be a life saving therapy for aggressive cancers.

For more details about technology: Click here

Broad Spectrum Antiviral Polysaccharide_Microbial Technology

Technology relates to a Broad-Spectrum Antiviral Polysaccharides from the marine, heterotrophic, microalgae called thraustochytrids, these microalgae also produce the omega-3 fatty acid, DHA. Therefore, this is an economical process to produce two valuable compounds from safe microorganisms. Proposed Technology addresses following Viruses: Enterovirus, Retrovirus, Cytomegalovirus, Adenovirus, Herpes simplex virus.

For more details about technology: Click here

Back To Top